Selected article for: "blood cell distribution and cell distribution"
Author: Martín-Quirós, Alejandro; Maroun-Eid, Charbel; Avendaño-Ortiz, José; Lozano-Rodríguez, Roberto; Valentín Quiroga, Jaime; Terrón, Verónica; Montalbán-Hernández, Karla; García-Garrido, Miguel A.; Muñoz del Val, Elena; del Balzo-Castillo, Álvaro; Rubio, Carolina; Cubillos-Zapata, Carolina; Aguirre, Luis A.; López-Collazo, Eduardo
Title: Potential Role of the Galectin-9/TIM-3 Axis in the Disparate Progression of SARS-CoV-2 in a Married Couple: A Case Report
  • Cord-id: b8xhlab8
  • Document date: 2021_4_19
    • ID: b8xhlab8
    Snippet: We report the disparate clinical progression of a couple infected by SARS-CoV-2 based on their immune checkpoint (IC) levels and immune cell distribution in blood from admission to exitus in patient 1 and from admission to discharge and recovery in patient 2. A detailed clinical follow-up accompanied by a longitudinal analysis of immune phenotypes and IC levels is shown. The continuous increase in the soluble IC ligand galectin-9 (Gal-9) and the increment in T-cell immunoglobulin and mucin domai
    Document: We report the disparate clinical progression of a couple infected by SARS-CoV-2 based on their immune checkpoint (IC) levels and immune cell distribution in blood from admission to exitus in patient 1 and from admission to discharge and recovery in patient 2. A detailed clinical follow-up accompanied by a longitudinal analysis of immune phenotypes and IC levels is shown. The continuous increase in the soluble IC ligand galectin-9 (Gal-9) and the increment in T-cell immunoglobulin and mucin domain-containing 3 (TIM-3) protein in T cells in patient 1 suggests an activation of the Gal-9/TIM-3 axis and, subsequently, a potential cell exhaustion in this patient that did not occur in patient 2. Our data indicate that the Gal-9/TIM-3 axis could be a potential target in this clinical setting, along with a patent effector memory T-cell reduction.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory distress syndrome and lmwh prophylactic dose: 1
    • acute respiratory distress syndrome and lmwh therapeutic dose: 1
    • acute respiratory distress syndrome and longitudinal analysis: 1, 2, 3, 4, 5
    • acute respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and low grade fever: 1, 2, 3, 4, 5
    • acute respiratory distress syndrome and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute respiratory distress syndrome and low remain: 1
    • lmwh low molecular weight heparin and lopinavir ritonavir: 1, 2, 3
    • lmwh low molecular weight heparin and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • lmwh low molecular weight heparin and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • lmwh prophylactic dose and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • lmwh prophylactic dose and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • lmwh therapeutic dose and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • lmwh therapeutic dose and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • lopinavir ritonavir and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • lopinavir ritonavir and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
    • lopinavir ritonavir and low remain: 1